Safety and tolerability of iodixanol. A dimeric, nonionic contrast medium: an emphasis on European clinical phases I and II.
Bolstad
B
B
Clinical R&D, Nycomed AS, Oslo, Norway.
Borch
K W
KW
Grynne
B H
BH
Lundby
B
B
Nossen
J O
JO
Kloster
Y F
YF
Kristoffersen
D T
DT
Andrew
E
E
D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005060:Europe; D006801:Humans; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000009:adverse effects*
D003287:Contrast Media; D014283:Triiodobenzoic Acids; C044834:iodixanol